Mammon Omicron Acquisition Corp
Blank-check shell seeking a $60M IPO, no business, no target, no revenue yet.
On the record
Checkpoint: IPO pricing/close on Nasdaq, and start of 18-month deadline to find a merger target
The call
This is a Cayman Islands cash shell still trying to price its IPO eight months after filing, with no merger target and no operating business to assess.
Mammon Omicron is a blank-check company, meaning it raised money from investors with no specific business to invest in yet. It has no revenue, no customers, and no employees because it does not operate anything. The company faces a hard deadline: if it does not find and complete a purchase of another company within 18 months, it must shut down and return the money to shareholders. There is no competitor or AI threat here because there is nothing to compete with or replace. The only thing that matters now is whether the company can announce a real acquisition target soon, since eight months after filing, it still has not even been allowed to start trading on the stock exchange.
Why
01
AI pressure: None apparent. There is no product or customer base for AI to disrupt; this is a cash shell hunting for a deal. Could AI do the core job? Yes, likely.
02
Bigger players: Larger, better-capitalized 2026 SPAC vehicles. Bigger SPACs with more cash and track records are competing for the same scarce merger targets and investor dollars. Could a giant copy it? Yes, easily.
03
What protects it. None identified: no operating business, no moat, no target company to defend.
What would change this call
Mammon Omicron's IPO prices and closes on Nasdaq. Shows the shell can raise capital despite an 8-month stall.
Public announcement of a named merger target or letter of intent. Marks the point the evaluation shifts to the target company's business.
Shareholder redemption or extension vote before the 18-month deadline. Signals the SPAC is failing to find or close a deal.
Public announcement of a named merger target or letter of intent. Marks the point the evaluation shifts to the target company's business.
Shareholder redemption or extension vote before the 18-month deadline. Signals the SPAC is failing to find or close a deal.
Key numbers
- $60M target raise via 6M units at $10.00 each
- $0 revenue, $0 customers, no employees
- Founder shares: 1,650,000 for $25,000 cost
Named risks
- IPO has not priced 8 months after S-1 filing, jeopardizing the offering entirely.
- No merger target identified as of latest filings, with 18-month combination clock not yet started.
- Management (CEO Jingjing Wu, CFO Guoliang Ge) has zero prior SPAC experience.
- China-linked sponsor background may draw heightened US regulatory scrutiny of the offering or future merger approval.
- Sub-scale $60M raise versus larger 2026 vintage SPACs reduces competitiveness for quality targets and capital.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Market Technology Acquisition Corp | losing to | Closed $205M IPO Jul 27, 2026 while Mammon Omicron's $60M offering remains unpriced |
| Burtech Acquisition Corp II, FortuneX, RRE Ventures Acquisition Corp and other 2026 SPACs | contesting | Competing for same pool of viable targets and SPAC-focused investor capital as of Jul 2026 |
| Chardan Capital Markets sponsor network peers | losing to | Larger, better-capitalized, more experienced sponsors closing deals while Mammon Omicron stalls 8 months post-S-1 |
Questions people ask
- Is Mammon Omicron Acquisition Corp profitable?
- No. It is a pre-revenue Cayman Islands blank-check SPAC shell with $0 revenue and $0 net income as of December 1, 2025, and no operating business, customers, or employees exist to generate income.
- Has Mammon Omicron Acquisition Corp's IPO priced yet?
- As of July 23, 2026, Mammon Omicron does not appear on Nasdaq's list of completed 2026 IPOs, despite filing its S-1 on December 2, 2025, roughly eight months earlier, meaning its proposed $60 million IPO has still not priced or closed.
- Does Mammon Omicron Acquisition Corp have a merger target?
- No target has been announced. As of the underwriting agreement dated September 29, 2025, the company disclosed no specific business combination under consideration and no substantive discussions with any target; SPAC Research lists the target company as TBD.
- Is it safe to invest in or join Mammon Omicron Acquisition Corp?
- It is a first-time, China-linked sponsor SPAC with no prior SPAC management experience among its CEO Jingjing Wu and CFO Guoliang Ge, an unpriced $60 million offering stalled eight months post-filing as of July 2026, and no announced merger target.
- Who leads Mammon Omicron Acquisition Corp?
- CEO and Chairman Jingjing Wu, also chairman of Mammon Global since May 2025 and former CEO of Xinghui Auto Technology (Hainan) Co., and CFO Guoliang Ge, founder/CEO of Shanghai TransForce Information Technology, as disclosed December 2, 2025.
- Who is underwriting Mammon Omicron Acquisition Corp's IPO?
- Chardan Capital Markets, LLC is the lead underwriter and bookrunner, per the underwriting agreement dated September 29, 2025, with units priced to underwriters at $9.55 versus the $10.00 public offering price.
Timeline
- 2026-07-23MMON still absent from Nasdaq's 2026 completed IPO list, unpriced 8 months after S-1
- 2026-06-21Placeholder market cap of ~$77.08M listed with no active trading data
- 2025-12-02S-1 registration filed with SEC proposing $60M IPO, 6,000,000 units at $10.00 each
- 2025-09-29Underwriting agreement executed with Chardan Capital Markets; no merger target disclosed
- 2025-08-22Sponsor issued additional 287,500 founder shares
- 2025-07-25Sponsor received 1,437,500 founder ordinary shares for $25,000
- 2025-05-01CEO Jingjing Wu became chairman of Mammon Global
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Mammon Omicron Acquisition Files for $60M IPO (2025-12-02)
- All 2026 IPOs (so far) (2026-07-23)
- Mammon Omicron Acquisition Corp. (2025-12-01)
- Underwriting Agreement between Mammon Omicron Acquisition Corp (2025-09-29)
- Mammon Omicron Acquisition (MMON) Company Profile & Description (2026-02-05)
- Mammon Omicron Acquisition Corp (2025-12-01)
- SPAC Mammon Omicron Acquisition files for a $60 million IPO, led by Chinese executives (2025-12-01)
- Market Technology Acquisition Corp Announces Closing of $205,000,000 Initial Public Offering (2026-07-27)
- Mammon Omicron Acquisition (MMON) Stock Price & Overview (2026-07-01)
- Mammon Omicron Acquisition (MMON) Statistics & Valuation (2026-06-21)